p53 Expression in Non-Hodgkin's Lymphomas: A Marker of p53 Inactivation?

References

• Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705–707
   PubMed Web of Science ®Google Scholar
• Levine A.J., Momand J., Finlay C.A. The p53 tumor suppressor gene. Nature 1991; 351: 453–456
   PubMed Web of Science ®Google Scholar
• Mashal R., Shtalrid M., Talpaz M., Kantarjian H., Smith L., Beran M., Cork A., Trujillo J., Gutterman J., Deisseroth A. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75: 180–189
   PubMed Web of Science ®Google Scholar
• Feinstein E., Cimino G., Gale R.P., Alimena G., Berthier R., Kishi K., Goldman J., Zaccaria A., Berrebi A., Canaani E. p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. USA 1991; 88: 6293–6297
   PubMed Web of Science ®Google Scholar
• Sander C.A., Yano, Clark H.M., Harris C., Longo D.L., Jaffe E.S., Raffeld M. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994–2004
   PubMed Web of Science ®Google Scholar
• Villuendas R., Piris M.A., Orradre J.L., Mollejo M., Algara P., Sanchez L., Martinez J.C., Martinez P. P53 protein expression in lymphomas and reactive lymphoid tissue. J. Pathol. 1992; 166: 235–241
   PubMed Web of Science ®Google Scholar
• Nakamura H., Said J.W., Miller C.W., Koeffler H.P. Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphoma. Blood 1993; 3: 920–926
   Google Scholar
• Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1993; 88: 5413–5417
   Web of Science ®Google Scholar
• Lo-Coco F., Gaidano G., Louie D., Offit K., Chaganti R., Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289–2295
   PubMed Web of Science ®Google Scholar
• Cesarman E., Inghirami G., Chadburn A., Knowles D.M. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am. J. Pathol. 1993; 143: 845–856
   PubMed Web of Science ®Google Scholar
• Ballerini P., Gaidano G., Gong J.Z., Tassi V., Saglio G., Knowles D.M., Dalla-Favera R. Multiple genetic lesions in Acquired Immunodeficiency Syndrome-related non-Hodgkin's Lymphoma. Blood 1993; 81: 166–176
   PubMed Web of Science ®Google Scholar
• Ichikawa A., Hotta T., Takagi N., Kinoshita T., Nagai H., Murakami Y., Hayashi K., Saito H. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992; 79: 2701–2707
   PubMed Web of Science ®Google Scholar
• Villuendas R., Piris M.A., Algara P., Sanchez-Beato M., Sanchez-Verde L., Martinez J.C., Orradre J.L., Garcia P., Lopez C., Martinez P. The expression of p53 protein in non-Hodgkin's is not always dependent on p53 gene mutations. Blood 1993; 82: 3151–3156
   PubMed Web of Science ®Google Scholar
• Piris M.A., Pezzella F., Martinez-Montero J.C., Orradre J.L., Villuendas R., Sanchez-Beato M., Cuena R., Cruz M.A., Martinez B., Garrido M.C., Gatter K., Aiello A., Delia D., Giardini R., Rilke F. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br. J. Cancer 1994; 69: 337–341
   PubMed Web of Science ®Google Scholar
• Finlay C.A., Hinds P.W., Levine A.J. The p53 protoncogen can act as a suppressor of transformation. Cell 1989; 57: 261–263
   Web of Science ®Google Scholar
• Hinds P.C., Finlay, Levine A.J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 1989; 63: 739–746
   PubMed Web of Science ®Google Scholar
• Lane D., Benchimol S. Oncogene or anti-oncogene?. Genes Dev. 1990; 4: 1–3
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Kinzler K.W. p53 function and disfunction. Cell 1992; 70: 523–526
   PubMed Web of Science ®Google Scholar
• Montenarh M. Biochemical properties of the growth sup-pressor/oncoprotein p53. Oncogene 1992; 7: 1673–1680
   PubMed Web of Science ®Google Scholar
• Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307–318
   PubMed Web of Science ®Google Scholar
• Hall P.A., McKee P.H., Menage H.P., Dover R., Lane D. High levels of p53 protein in uv-irradiated normal human skin. Oncogene 1993; 8: 203–207
   PubMed Web of Science ®Google Scholar
• El-Diery W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer E., Kinzler K.W., Vogesltein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805–816
   PubMed Web of Science ®Google Scholar
• Xiong P., Hannon G., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–704
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345–347
   PubMed Web of Science ®Google Scholar
• Yin Y., Tainsky M.A., Farideh Z.B., Strong L.C., Wahl G.M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937–948
   PubMed Web of Science ®Google Scholar
• Aloni-Grinstein R., Zan-Bar I., Alboum I., Goldfinger N., Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the b-cell lineage. Oncogene 1993; 8: 3297–3305
   PubMed Web of Science ®Google Scholar
• Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747–749
   PubMed Web of Science ®Google Scholar
• Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.H., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215–221
   PubMed Web of Science ®Google Scholar
• Milner J., Medcalf E.A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991; 65: 765–774
   PubMed Web of Science ®Google Scholar
• Iggo R., Gatter K., Bartek J., Lane D., Harris A.L. Increased expression of mutant forms of p53 oncogen in primary lung cancer. Lancet 1990; 335: 675–679
   PubMed Web of Science ®Google Scholar
• Finlay C.A., Hinds P.W., Tan T.H., Aliyahu D., Oren M., Levin J. Activating mutations for transformation by p53 produce a gene produce that forms hsc70-p53 complex with an altered half life. Mol. Cell. Biol. 1988; 8: 531–539
   PubMed Web of Science ®Google Scholar
• Crook T., Wrede D., Tidy J.A., Mason W.P., Evan D.J., Vousdn K.H. Clonal p53 mutation in primary cervical cancer: Association with human papillomavirus negative tumors. Lancet 1992; 339: 1070–1073
   PubMed Web of Science ®Google Scholar
• Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howly P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promoted the degradation of p53. Cell 1990; 63: 1129–1136
   PubMed Web of Science ®Google Scholar
• Modmand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245
   PubMed Web of Science ®Google Scholar
• Barak Y., Juven T., Haffner R., Oren M. MDM2 expression is induced by wild type p53 activity. EMBOJ. 1993; 12: 461–468
   PubMed Web of Science ®Google Scholar
• Wu X., Bayle J.H., Olson D., Levine A.J. The p53-mdm-2 autoregulatory feedback loop. Genes & Dev. 1993; 7: 1126–1132
   PubMed Web of Science ®Google Scholar
• Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-as-sociated protein in human sarcomas. Nature 1992; 358: 80–83
   PubMed Web of Science ®Google Scholar
• Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857–860
   PubMed Web of Science ®Google Scholar
• Reiferberger G., Liu L., Ichimura K., Schmidt E.E., Collins V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993; 53: 2736–2739
   PubMed Web of Science ®Google Scholar
• Bartek J., Iggo R., Gannon J., Lane D.P. Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893–899
   PubMed Web of Science ®Google Scholar
• Thor A.D., Moore D.H., Edgerton S., Kawasaki E., Reihsaus E., Lynch H.T., Marcus J.N., Schwartz L., Chen L., Mayall B.H., Smith H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst. 1992; 84: 845–855
   PubMed Web of Science ®Google Scholar
• Bennet W.P., Hollstein M.C., He A., Zhu, Resau J.H., Trump B.F., Metcalf R.A., Welsh J.A., Midgley C., Lane D.P., Harris C.C. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene 1991; 6: 1779–1784
   PubMed Web of Science ®Google Scholar
• Marks J.R., Davidoff A.M., Kerns B.J., Humphrey P.A., Pence J.C., Dodge R.K., Clarke-Pearson D.L., Iglehart J.D., Bast R.C., Berchuck A. Overexpression and mutations of p53 in epithelial ovarian cancer. Cancer Res. 1991; 51: 2979–2984
   PubMed Web of Science ®Google Scholar
• Rodrigues N.R., Rowan A., Smith R.E., Kerr I.B., Bodmer W.F., Gannon J.V., Lane D. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 1990; 87: 7555–7559
   PubMed Web of Science ®Google Scholar
• Baas I.O., Mulder J. W. R., Offerhans G. J. A., Vogelstein B., Hamilton S.R. An evaluation of si antibodies for immunohistochemistry off mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 1994; 172: 5–12
   PubMed Web of Science ®Google Scholar
• Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990; 9: 1595–1602
   PubMed Web of Science ®Google Scholar
• Halevy O., Hall A., Oren M. Stabilization of the p53 transformation-related protein in luse fibrosarcoma cell lines: effects of protein sequence and intracellular environment. Mol. Cell. Biol. 1989; 9: 3385–3392
   PubMed Web of Science ®Google Scholar
• Banks S.J., Matlashewiski G., Crawford L. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 1986; 159: 529–534
   PubMedGoogle Scholar
• McKee P.H., Hobbs C., Hall P.A. Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathol. 1993; 23: 377–379
   PubMed Web of Science ®Google Scholar
• Reich N.C., Levine A.J. Growth regulation of a cellular tumours antigen p53, in non transformed cells. Nature 1984; 308: 199–201
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P., Oates J., Kittas C., Crocker J. p53, c-myc, p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas. J. Clin. Pathol. 1994; 47: 9–14
   PubMed Web of Science ®Google Scholar
• Dowell S., Derias N., Wilson P. O. G., Lane D.P., Hall P.A. Expression of p53 in reactive mesotelium. Histophatol. 1993; 22: 96–97
   PubMed Web of Science ®Google Scholar
• Heyderman E., Dagg B. p53 immunostatning in benign breast disease. Lancet 1991; 338: 1532
   PubMed Web of Science ®Google Scholar
• Dei Tos A.P., Doglioni C., Laurino L., Barbareschi M., Fletcher C. D. M. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathol. 1993; 22: 45–50
   PubMed Web of Science ®Google Scholar
• Tadini G., Cerri A., Crosti L., Cattoretti G., Berti E. p53 and oncogenes expression in psoriasis. Acta Derm Venereal (Stockh) 1989; 146: 33–35
   Google Scholar
• Milner J., Watson J.V. Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein. Oncogene 1990; 5: 1683–1690
   PubMed Web of Science ®Google Scholar
• Pezzella F., Micklem K., Turley H., Pulford K., Jones M., Koialkowski S., Delia D., Aiello A., Bicknell R., Smith K., Harris A.L., Gatter K.C., Mason D.Y. p53 protein is widely detected by immunostaining in normal human tissues. J. Clin. Pathol. 1994, in press
   PubMed Web of Science ®Google Scholar
• Soini Y., Pääkko P., Alavaikko M., Vähäkangas K. p53 expression in lymphatic malignancies. J. Clin. Pathol. 1992; 45: 1011–1014
   PubMed Web of Science ®Google Scholar
• Said J.W., Barrera R., Shintaku I.P., Nakamura H., Koeffler H.P. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am. J. Pathol. 1992; 141: 1343–1348
   PubMed Web of Science ®Google Scholar
• Pezzella F., Morrison H., Jones M., Gatter K.C., Lane D., Harris A.L., Mason D.Y. Immunohistochemical detection of p53 and bcl2 proteins in non-Hodgkin's lymphoma. Histopathol. 1993; 22: 39–44
   PubMed Web of Science ®Google Scholar
• Doglioni C., Pelosio P., Mombello A., Scarpa A., Chilosi M. Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease andCD30+anaplastic lymphomas. Hematol. Pathol., S 1991; 67–73
   Google Scholar
• Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767
   PubMed Web of Science ®Google Scholar
• Sidransky D., Mikkelsen T., Schwechheimer K., Rosemblum M.L., Cavanee W., Vogelstein B. Clonal expansion of p53 mutant cell is associated with brain tumor progression. Nature 1992; 355: 846–847
   PubMed Web of Science ®Google Scholar
• El-Rouby S., Thomas A., Costin D., Rosenberg C.R., Potmesil M., Silber R., Newcomb E.W. p53 gene mutation in B-cell chronic leukemia is associated with drug resistence and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Bressak B., Galvin K.M., Liang T.J., Isselbacher K.J., Wands J.R., Ozturk M. Abnormal structure and expression of p53 in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 1990; 87: 1973–1977
   PubMed Web of Science ®Google Scholar
• Brash D.E., Rudolph J.A., Simon J.A., Lin A., McKenna G.J., Baden H.P., Halperin A.J., Ponten J. A role for sunlight in skin cancer: UV induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 1991; 88: 10124–10128
   PubMed Web of Science ®Google Scholar
• Ziegler A., Leffell D.J., Kunala S., Sharma H.W., Gailani M., Simon J.A., Baden H.P., Shapiro P.E., Bale A.E., Brash D.E. Mutations hotspot due to sunlight in the p53 gene of non melanoma skin cancer. Proc. Natl. Acad. Sci. USA 1993; 90: 4216–4220
   PubMed Web of Science ®Google Scholar
• Caron de Fromentel C., Soussi T. TP53 tumour supressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992; 4: 1–15
   PubMed Web of Science ®Google Scholar
• Rideout W.M., Coetzee G.A., Olumi A.F., Jones P.A. 5-MethylCytosine as an endogenous mutagen in the human LDL re-ceptorand p53 gene. Science 1990; 249: 1288–1290
   PubMed Web of Science ®Google Scholar
• Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T. p53 is frequently mutated in Burkitt's lymphomacell lines. EMBO J. 1991; 10: 2879–2887
   PubMed Web of Science ®Google Scholar
• Reid R.L., Lindholm P.F., Mireskandari A., Dittmer J. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-1. Oncogene 1993; 8: 3029–3036
   PubMed Web of Science ®Google Scholar
• Matsushima A.Y., Cesarman E., Knowles D.M. Mutations are not detected outside p53 gene exons 5 to 9 in lymphoid tumours. Lab. Invest. 1994; 70: 115A
   Web of Science ®Google Scholar
• Cabanillas F., Pathak S., Grant G., Hagemeister F.B., McLaughlin P., Swan F., Rodriguez M.A., Trujillo J., Cork A., Butler J.J., Katz R., Bourne S., Freireich E.J. Refractoriness to Chemotherapy and poor survival related to abnormalities of chromosome 17 and 7 in lymphoma. Am. J. Med. 1989; 87: 167–172
   PubMed Web of Science ®Google Scholar
• Levine E.G., Arthur D.C., Frizzera G., Peterson B.A., Hurd D.D., Bloomfield C.D. Cytogenetic Abnormalities predict clinical outcome in non-Hodgkin lymphoma. Ann. Intern. Med. 1988; 108: 14–20
   PubMed Web of Science ®Google Scholar
• Rodriguez M.A., Ford R.J., Goodacre A., Selvanayagam P., Cabanillas F., Deisseroth A.B. Chromosome 17p and p53 changes in lymphoma. Br. J. Haematol. 1991; 79: 575–582
   PubMed Web of Science ®Google Scholar
• Schouten H.C., Sanger W.G., Weisenburger D.D., Anderson J., Armitage J.O. Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. Blood 1990; 75: 1841–1847
   PubMed Web of Science ®Google Scholar
• Chin K.V., Ueda K., Pastan I., Gottesman M.M. Modulation of activity of the promoter of the human MDRI gene by Ras and p53. Science 1992; 255: 459–462
   PubMed Web of Science ®Google Scholar
• Scott N., Sgar P., Stewart J., Blair G.E., Dixon M.F., Quirke P. p53 in colorectal cancer: Clinicopathological correlation and prognostic significance. Br. J. Cancer 1991; 63: 317–319
   PubMed Web of Science ®Google Scholar
• Allred D.C., Clark G.M., Elledge R., Fuqua S. A. W., Brown R.W., Chamness G.C., Osborne C.K., McGuire W.L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 1993; 85: 200–206
   PubMed Web of Science ®Google Scholar
• Sarkis A.S., Dalbagni G., Cordon-Cardo C., Zhang Z.F., Sheinfeld J., Fair W.R., Herr H.W., Reuter V.E. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J. Natl. Cancer Inst. 1993; 85: 53–59
   PubMed Web of Science ®Google Scholar
• Martin H.M., Filipe M.I., Morris R.W., Lane D.P., Silvestre F. p53 expression and prognosis in gastric carcinoma. Int. J. Cancer 1992; 50: 859–862
   PubMed Web of Science ®Google Scholar
• Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52: 4828–4831
   PubMed Web of Science ®Google Scholar
• Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T., Shimokata K., Yamakawa K., Nakamuar Y., Ueda R., Takahashi T. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993; S3: 1–4
   Google Scholar
• Visakorpi T., Kallionemi O.P., Heikkinen A., Koivula T., Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst. 1992; 84: 883–887
   PubMed Web of Science ®Google Scholar
• Cesarman E., Chadbum A., Inghirami G., Gaidano G., Knowles D.M. Structural and functional analysis of oncogenes and tumour suppressor genes in adult T-cell leukemia/lym-phoma shows frequent p53 mutations. Blood 1992; 80: 3205–3216
   PubMed Web of Science ®Google Scholar
• Szekely L., Selivanova G., Magnusson K.P., Klein G., Wiman K.G. EBNA-5, an Epstein-Barr virus encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. 1993; 90: 5455–5459
   PubMed Web of Science ®Google Scholar